Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/07/08 20:56:18」(JST)
[Wiki en表示]
Garenoxacin
|
| Systematic (IUPAC) name |
|
1-Cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
|
| Clinical data |
Routes of
administration |
Oral |
| Identifiers |
| CAS Registry Number |
194804-75-6 N |
| ATC code |
J01MA19 |
| PubChem |
CID: 124093 |
| ChemSpider |
110579 N |
| UNII |
V72H9867WB Y |
| KEGG |
D04031 Y |
| Chemical data |
| Formula |
C23H20F2N2O4 |
| Molecular mass |
426.412 g/mol |
SMILES
-
FC(F)Oc1c(ccc2c1N(/C=C(\C2=O)C(=O)O)C3CC3)c4ccc5c(c4)CN[C@@H]5C
|
InChI
-
InChI=1S/C23H20F2N2O4/c1-11-15-5-2-12(8-13(15)9-26-11)16-6-7-17-19(21(16)31-23(24)25)27(14-3-4-14)10-18(20(17)28)22(29)30/h2,5-8,10-11,14,23,26H,3-4,9H2,1H3,(H,29,30)/t11-/m1/s1 N
-
Key:NJDRXTDGYFKORP-LLVKDONJSA-N N
|
| N (what is this?) (verify) |
Garenoxacin (INN) is a quinolone antibiotic for the treatment of Gram-positive and Gram-negative bacterial infections.
Garenoxacin was discovered by Toyama Chemical Co., Ltd. of Tokyo, Japan, and is currently being marketed in Japan under the tradename Geninax. Schering-Plough holds worldwide rights for garenoxacin, except for Japan, South Korea, and China.
On February 13, 2006, Schering-Plough announced that the United States Food and Drug Administration has accepted the New Drug Application (NDA) for garenoxacin, and has been granted a 10-month review.[1]
Schering-Plough later withdrew its application to the United States Food and Drug Administration, FDA, (August 20, 2006) for approval of the antibiotic Garenoxacin.[2]
The European Medicines Agency (EMEA) had also been formally notified by Schering-Plough Europe (July 28 2007) of its decision to withdraw the application for a centralized marketing authorization for garenoxacin as well.[3][4][5] Based on the CHMP review of the data regarding safety and efficacy (risk/benefit), the CHMP considered the application for garenoxacin to be unapprovable.[6]
References
- ^ "Drugs.com, Schering-Plough Reports Garenoxacin NDA Accepted for FDA Review". Retrieved 2008-03-25.
- ^ http://www.fiercebiotech.com/story/schering-plough-pulls-its-garenoxacin-app/2006-08-21
- ^ http://www.medicalnewstoday.com/articles/78052.php
- ^ http://www.emea.europa.eu/humandocs/PDFs/EPAR/garenoxacinmesylate/34117407en.pdf
- ^ http://www.emea.europa.eu/humandocs/PDFs/EPAR/garenoxacinmesylate/H-747-WAR.pdf
- ^ http://www.emea.europa.eu/humandocs/PDFs/EPAR/garenoxacinmesylate/H-747-WAR.pdf
|
Antibacterials: nucleic acid inhibitors (J01E, J01M)
|
|
Antifolates
(inhibits
purine metabolism,
thereby inhibiting
DNA and RNA synthesis) |
| DHFR inhibitor |
- 2,4-Diaminopyrimidine
- Brodimoprim
- Diaveridine
- Iclaprim†
- Ormetoprim
- Trimethoprim#
- Tetroxoprim
|
|
Sulfonamides
(DHPS inhibitor) |
Short-
acting |
- Sulfaisodimidine
- Sulfamethizole
- Sulfadimidine
- Sulfapyridine
- Sulfafurazole
- Sulfanilamide
- Sulfathiazole
- Sulfathiourea
|
|
Intermediate-
acting |
- Sulfamethoxazole
- Sulfadiazine#
- Sulfamoxole
|
|
Long-
acting |
- Sulfadimethoxine
- Sulfadoxine
- Sulfalene
- Sulfametomidine
- Sulfametoxydiazine
- Sulfamethoxypyridazine
- Sulfaperin
- Sulfamerazine
- Sulfaphenazole
- Sulfamazone
|
|
| Other/ungrouped |
- Sulfacetamide
- Sulfadicramide
- Sulfametrole
|
|
|
| Combinations |
- Trimethoprim/sulfamethoxazole#
|
|
|
Topoisomerase
inhibitors/
quinolones/
(inhibits
DNA replication) |
| 1st g. |
- Cinoxacin‡
- Flumequine
- Nalidixic acid
- Oxolinic acid
- Pipemidic acid
- Piromidic acid
- Rosoxacin
|
|
Fluoro-
quinolones |
| 2nd g. |
- Ciprofloxacin#
- Enoxacin‡
- Fleroxacin‡
- Lomefloxacin
- Nadifloxacin
- Ofloxacin
- Norfloxacin
- Pefloxacin
- Rufloxacin
|
|
| 3rd g. |
- Balofloxacin
- Grepafloxacin‡
- Levofloxacin
- Pazufloxacin
- Sparfloxacin‡
- Temafloxacin‡
- Tosufloxacin
|
|
| 4th g. |
- Besifloxacin
- Clinafloxacin†
- Garenoxacin
- Gemifloxacin
- Moxifloxacin
- Gatifloxacin‡
- Sitafloxacin
- Trovafloxacin‡/Alatrofloxacin‡
- Prulifloxacin
|
|
| Vet. |
- Danofloxacin
- Difloxacin
- Enrofloxacin
- Ibafloxacin
- Marbofloxacin
- Orbifloxacin
- Pradofloxacin
- Sarafloxacin
|
|
| Related (DG) |
- Aminocoumarins: Novobiocin
|
|
|
|
Anaerobic DNA
inhibitors |
| Nitro- imidazole derivatives |
- Metronidazole#
- Tinidazole
- Ornidazole
|
|
| Nitrofuran derivatives |
- Nitrofurantoin#
- Furazolidone‡
- Nifurtoinol
|
|
|
| RNA synthesis |
Rifamycins/
RNA polymerase |
- Rifampicin#
- Rifabutin
- Rifapentine
- Rifaximin
|
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
Index of bacterial disease
|
|
| Description |
|
|
| Disease |
- Gram-positive firmicutes
- Gram-positive actinobacteria
- Gram-negative proteobacteria
- Gram-negative non-proteobacteria
- Cholera
- Tuberculosis
|
|
| Treatment |
- Antibiotics
- cell wall
- nucleic acid
- mycobacteria
- protein synthesis
- other
- Antibodies
|
|
|
English Journal
- Molecular characterization of quinolone-insensitive Streptococcus pneumoniae isolates from Japanese patients.
- Araki N, Yanagihara K, Matsukawa Y, Harada Y, Migiyama Y, Nagaoka K, Yamada K, Morinaga Y, Hasegawa H, Kohno S, Kamihira S.SourceDepartment of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
- Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.J Infect Chemother.2013 Apr;19(2):356-9. doi: 10.1007/s10156-012-0461-0. Epub 2012 Aug 22.
- Fluoroquinolone resistance in Streptococcus pneumoniae has become a growing concern. Using S. pneumoniae isolates (n = 61) for which the minimum inhibitory concentration (MIC) of levofloxacin was not less than 1 μg/ml, we investigated the susceptibility of S. pneumoniae isolates to other fluoroq
- PMID 22911090
- In vitro activities of levofloxacin, gatifloxacin, moxifloxacin and garenoxacin against Bacteroides fragilis strains evaluated by kill kinetics.
- Schaumann R, Janssen E, Funke M, Stîngu CS, Genzel GH, Janssen M, Rodloff AC.SourceInstitute for Medical Microbiology and Epidemiology of Infectious Diseases, University of Leipzig, Leipzig, Germany. reiner.schaumann@medizin.uni-leipzig.de
- Journal of medical microbiology.J Med Microbiol.2013 Apr;62(Pt 4):576-81. doi: 10.1099/jmm.0.053280-0. Epub 2013 Jan 14.
- This study was designed to investigate the killing activity of levofloxacin, gatifloxacin, moxifloxacin and garenoxacin against 12 Bacteroides fragilis strains by kill kinetics over time. MIC values were determined by Etest and by agar dilution. B. fragilis strains were divided according to their MI
- PMID 23319309
Japanese Journal
- Pharmacokinetic study of garenoxacin in severe renal failure patients
- YAMAGISHI YUKA,HAGIHARA MAO,HAMADA YUKIHIRO [他]
- The Japanese journal of antibiotics 68(3), 141-150, 2015-06
- NAID 40020517292
- 5.EBUS-TBNAによる縦隔リンパ節中Garenoxacin濃度の測定(第36回 日本呼吸器内視鏡学会北海道支部会)
- 遠藤 哲史,平井 理子,風林 佳大,南 幸範,奥村 俊介,佐々木 高明,山本 泰司,長内 忍,大崎 能伸
- 気管支学 : 日本気管支研究会雑誌 36(6), 681, 2014-11-25
- NAID 110009878738
Related Links
- Garenoxacin was discovered by Toyama Chemical Co., Ltd. of Tokyo, Japan, and is currently being marketed in Japan under the tradename Geninax. Schering- Plough holds worldwide rights for garenoxacin, except for Japan, South Korea, ...
- 日本における発売年. 2007（平成19）年. 3. 特長. 呼吸器・耳鼻咽喉科領域感染症の 主要起炎菌に適した抗菌スペクトルと優れた抗菌活性を有する（in vitro）。 多剤耐性 肺炎球菌にも優れた抗菌活性を示す（in vitro）。 1日1回投与で大きなAUC（血中濃度 曲線 ...
Related Pictures
![Garenoxacin synthesis: [ 7 ] N.B. [ 8 ]](https://1mg.info/0/7/7/1233.jpg)
★リンクテーブル★
[★]
- 英
- garenoxacin
- 同
- メシル酸ガレノキサシン水和物 garenoxacin mesilate hydrate
- 商
- ジェニナック
- 関
- 合成抗菌剤